Clinical Trials
59 trialsItacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
Children's Hospital Los Angeles
Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)
Thomas Jefferson University
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Thomas Jefferson University
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
Dana-Farber Cancer Institute
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
University of Colorado, Denver
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Mayo Clinic
GIST in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
Weill Medical College of Cornell University
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Baptist Health South Florida
ARIA
Ipsen
CEF-10
Hamad Medical Corporation
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Mayo Clinic
HemaSur
Rennes University Hospital
2019-KOE-001
Baptist Health South Florida
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
City of Hope Medical Center
Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study
Roswell Park Cancer Institute
EVAADE
Centre Leon Berard
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy
Case Comprehensive Cancer Center
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
OHSU Knight Cancer Institute
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
Psycho-Educational Cognition Intervention in Patients With Blood and Lymph Cancer
City of Hope Medical Center
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
HYACINTHE
Institut de cancérologie Strasbourg Europe
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Duke University
Consolidation Therapy in Patients With Hematologic Malignancies
Kiromic BioPharma Inc.
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Incyte Corporation
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Therapy for Progressive and/or Refractory Hematologic Malignancies
Kiromic BioPharma Inc.
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
Emory University
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Medical-legal Partnership (MLP) to Support Bone Marrow Transplant
University of Minnesota
Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Duke University
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Tarix Pharmaceuticals
Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)
Sheba Medical Center
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
Imperial College London